Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 4,015 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 4,015 shares of Clene stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $5.73, for a total value of $23,005.95. Following the completion of the transaction, the insider directly owned 766,480 shares in the company, valued at $4,391,930.40. This represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total transaction of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The shares were sold at an average price of $6.32, for a total transaction of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The stock was sold at an average price of $6.54, for a total transaction of $28,560.18.
• On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The shares were sold at an average price of $6.45, for a total value of $36,003.90.
• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total value of $36,815.28.

Clene Stock Performance

CLNN stock opened at $5.77 on Friday. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The firm has a market cap of $59.60 million, a P/E ratio of -1.70 and a beta of 0.87. The stock has a 50-day simple moving average of $8.06 and a 200-day simple moving average of $6.34.

Clene (NASDAQ:CLNN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts predict that Clene Inc. will post -5.19 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CLNN. Lunt Capital Management Inc. lifted its stake in Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after purchasing an additional 21,217 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Clene during the second quarter valued at $47,000. Scoggin Management LP lifted its position in Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after purchasing an additional 42,750 shares during the last quarter. Finally, Jones Financial Companies Lllp acquired a new position in Clene during the 3rd quarter valued at about $29,000. Institutional investors and hedge funds own 23.28% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Clene in a report on Wednesday, December 10th. UBS Group reissued a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).